Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083226 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00083226: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00083226 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083226, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving doxorubicin together with bortezomib may kill more tumor cells.
Interventions
- DRUG doxorubicin
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-03 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083226
The ClinicalTrials.gov registry entry for NCT00083226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin is the first listed.
NCT00083226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083226 about?
NCT00083226 is a clinical study titled "Doxorubicin and Bortezomib in Treating Patients With Liver Cancer". This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of ...
What is the current status of trial NCT00083226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2004-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00083226?
The interventions under investigation include: doxorubicin (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00083226?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.